Aquestive Therapeutics, a Warren-based pharmaceutical company, announced Sherry Korczynski has been elevated from senior vice president of Sales and Marketing to chief commercial officer effective July 22.
“Sherry’s promotion reflects her exceptional track record in commercial leadership within the allergy market,” Daniel Barber, president and chief executive officer of Aquestive said. “Her proven expertise —including her strategic oversight of the EpiPen® brand at Mylan—makes her uniquely qualified to drive our global commercial strategy for Anaphylm. With her deep market knowledge and demonstrated success in marketing, advocacy, public relations and sales execution, Sherry is perfectly positioned to lead our efforts as we bring Anaphylm to patients in the U.S. and abroad.”
Korczynski joined Aquestive in February 2024 to lead the company’s sales and marketing initiatives. With more than two decades of commercial and launch experience across leadership roles at ANI Pharmaceuticals, Eagle Pharmaceuticals, Mylan (now Viatris), and Eli Lilly & Company, she holds deep expertise in allergy therapeutics, having led the marketing, public relations, and patient advocacy efforts for EpiPen.
